• Policy
• Drugs subject to 2nd evaluations may submit data by Oct
• by Lee, Tak-Sun Feb 9, 2023 05:50am

• Policy
• Enhertu's referral to the National Petition Welfare Committe
• by Lee, Jeong-Hwan Feb 9, 2023 05:49am

• Company
• 80 billion won worth of Anticonvulsant Market
• by Nho, Byung Chul Feb 9, 2023 05:49am

• Company
• Olumiant may land to treat alopecia areata in KOR this year
• by Eo, Yun-Ho Feb 9, 2023 05:49am

• Company
• Entresto’s sales exceeded KRW 40 billion last year
• by Feb 8, 2023 05:53am

• Policy
• Legislation of health functional foods
• by Lee, Jeong-Hwan Feb 8, 2023 05:53am

• Company
• Huonslab is speeding up the development of Prolia biosimilar
• by Lee, Seok-Jun Feb 8, 2023 05:53am

• Company
• Prescription of Celltrion’s Takeda drugs fall for 2 yrs
• by Kim, Jin-Gu Feb 8, 2023 05:53am

• Company
• The first reverse growth of NOAC worth 230 billion won
• by Jung, Sae-Im Feb 8, 2023 05:53am

• Company
• Dong-A Forxiga loses the patent dispute
• by Kim, Jin-Gu Feb 7, 2023 05:48am